A preclinical study demonstrated that CAR-T cell therapy targeting both BCMA and GPRC5D can reduce relapse caused by BCMA antigen escape and eliminate BCMA-negative multiple myeloma cells in a mouse model (23). Here, TNFRSF17 is linked to plasma cell myeloma.